Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes 3900, 14049-900 Ribeirão Preto, São Paulo, Brazil.
Endocrinology. 2012 May;153(5):2323-31. doi: 10.1210/en.2011-2079. Epub 2012 Mar 6.
We report changes in plasma arginine vasopressin (AVP) and oxytocin (OT) concentrations evoked by the microinjection of l-glutamate (l-glu) into the hypothalamic supraoptic nucleus (SON) and paraventricular nucleus (PVN) of unanesthetized rats, as well as which local mechanisms are involved in their mediation. l-Glu microinjection (10 nmol/100 nl) into the SON increased the circulating levels of both AVP and OT. The AVP increases were blocked by local pretreatment with the selective non-N-methyl-d-aspartate (NMDA) receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) (2 nmol/100 nl), but it was not affected by pretreatment with the NMDA-receptor antagonist LY235959 (2 nmol/100 nl). The OT response to l-glu microinjection into the SON was blocked by local pretreatment with either NBQX or LY235959. Furthermore, the administration of either the non-NMDA receptor agonist (±)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrobromide (AMPA) (5 nmol/100 nl) or NMDA receptor agonist NMDA (5 nmol/100 nl) into the SON had no effect on OT baseline plasma levels, but when both agonists were microinjected together these levels were increased. l-Glu microinjection into the PVN did not change circulating levels of either AVP or OT. However, after local pretreatment with LY235959, the l-glu microinjection increased plasma levels of the hormones. The l-glu microinjection into the PVN after the local treatment with NBQX did not affect the circulating AVP and OT levels. Therefore, results suggest the AVP release from the SON is mediated by activation of non-NMDA glutamate receptors, whereas the OT release from this nucleus is mediated by an interaction of NMDA and non-NMDA receptors. The present study also suggests an inhibitory role for NMDA receptors in the PVN on the release of AVP and OT.
我们报告了在未麻醉大鼠下丘脑视上核(SON)和室旁核(PVN)内微量注射 L-谷氨酸(l-glu)引起的血浆精氨酸加压素(AVP)和催产素(OT)浓度变化,以及涉及的局部机制。l-glu 微注射(10nmol/100nl)进入 SON 会增加循环中的 AVP 和 OT 水平。局部预先用选择性非 N-甲基-D-天冬氨酸(NMDA)受体拮抗剂 2,3-二氧代-6-硝基-1,2,3,4-四氢苯并[f]喹喔啉-7-磺酰胺(NBQX)(2nmol/100nl)预处理可阻断 AVP 增加,但用 NMDA 受体拮抗剂 LY235959(2nmol/100nl)预处理不影响 AVP 增加。l-glu 微注射进入 SON 引起的 OT 反应被局部用 NBQX 或 LY235959 预处理阻断。此外,NMDA 受体激动剂 NMDA(5nmol/100nl)或非 NMDA 受体激动剂(±)-α-氨基-3-羟基-5-甲基异恶唑-4-丙酸氢溴酸盐(AMPA)(5nmol/100nl)进入 SON 都不会改变 OT 的基础血浆水平,但当两种激动剂一起注射时,这些水平会增加。l-glu 微注射到 PVN 不会改变 AVP 或 OT 的循环水平。然而,在局部用 LY235959 预处理后,l-glu 微注射增加了激素的血浆水平。在 NBQX 局部处理后,l-glu 微注射到 PVN 不会影响循环中的 AVP 和 OT 水平。因此,结果表明 SON 中的 AVP 释放是由非 NMDA 谷氨酸受体的激活介导的,而来自该核的 OT 释放是由 NMDA 和非 NMDA 受体的相互作用介导的。本研究还表明,PVN 中的 NMDA 受体对 AVP 和 OT 的释放具有抑制作用。